Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... The new , Healthcare and Life Sciences Review ... PharmaBoardroom.com for free download , looks beyond ... economy in 2009, and the austerity measures that followed, to ... times of trouble. "Despite the crisis, ... and the general conditions to invest are favorable to the ...
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... Sweden has shown that biosynthetic corneas can help regenerate and ... results, from an early phase clinical trial with 10 patients, ... Science Translational Medicine . "This study is important because ... cornea can integrate with the human eye and stimulate regeneration," ...
... Enterprise Institute (Mtech) Bioprocess Scale-Up Facility (BSF) will double ... equipment, and create a pilot plant for biofuels in College ... from the Maryland Biotechnology Center . "The ... make sure the BSF,s capabilities are available to the growing ...
... bioserie is first to market with a line ... device owners the protection they demand while using only ... use of the latest in bioplastics technology offers considerably ... of environmental toxic pollution once the cover is discarded. ...
Cached Biology Technology:Seeing the world with new eyes: Biosynthetic corneas restore vision in humans 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 3bioserie Introduces the World's First 'Made of Plants' iPhone 4 Cover 2
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2
... painted with gold purify the air when they are ... of Technology experts have discovered. Associate Professor Zhu ... Sciences said that glaziers in medieval forges were the ... different sizes. Professor Zhu said numerous church ...
... detailed images of the body,s anatomy. Thanks to novel ... scientist Eric Ahrens, MRI can be used to visualize ... in the living body. The ability to non-invasively locate ... aid the study and treatment of cancer, inflammation, and ...
... August 20, 2008 New phase 2 data published ... investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic ... PTC124 results in statistically significant improvements in the chloride ... study was conducted at the Hadassah Hebrew University Hospital ...
Cached Biology News:Air-purifying church windows early nanotechnology 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
... fluorescent and highly photostable FluoSpheres microspheres ... a variety of applications requiring probes ... Unfortunately, protein- and other macromolecule-labeled microspheres ... them to bind to non-target surfaces ...
Goat polyclonal to Duffy / FY / DARC...
SMVT (N-14)...
... Description: Proteinase K is a highly ... range of applications purified from the fungus T. ... carboxyl group of N-substituted hydrophobic aliphatic and aromatic ... a serine protease. Proteinase K is useful in ...
Biology Products: